The high prevalence of metabolic syndrome in persons with schizophrenia has spurred
investigational efforts to study the mechanism beneath its pathophysiology. Early psychosis …

Schizophrenia, a serious psychiatric disorder, is among the top 10 global causes of disability
and affects nearly 1% of the world population. Antipsychotics constitute the best treatment for …

Background Many studies have explored the link between the gut microbiota and
schizophrenia. To date, there have been no bibliometric analyses to summarize the …

Aim Widely used second‐generation antipsychotics are associated with adverse metabolic
effects, contributing to increased cardiovascular mortality. To develop strategies to prevent …

Abstract Background Metabolic syndromes (MetS) are clinical syndromes involving multiple
pathological states with distinct gender-specific clinical patterns. As a serious disorder …

Abstract Background and Hypothesis Antipsychotics (APs), the cornerstone of schizophrenia
treatment, confer a relatively high risk of constipation. However, the mechanisms …

Bipolar disorders (BDs) are a heterogeneous group of severe affective disorders generally
described by the alternation of (hypo) manic, depressive, and mixed phases, with euthymic …

Abstract Purpose of Review Weight gain is a disconcerting issue experienced by patients
treated with antipsychotics (APs). This review summarizes current knowledge on the …

Schizophrenia is a chronic and often severe mental disorder for which antipsychotic drugs
are the cornerstone of treatment. Although the essential mechanism of action of these drugs …

Variants in the SLCO1B1 (solute carrier organic anion transporter family member 1B1) gene
encoding the OATP1B1 (organic anion transporting polypeptide 1B1) protein are associated …